Serine/threonine protein kinase
From Proteopedia
(Difference between revisions)
| Line 297: | Line 297: | ||
**[[6cj5]], [[6cje]], [[6cjh]], [[6cjw]], [[6cjy]], [[6ck3]], [[6ck6]], [[6cki]] – hChk 2 catalytic domain (mutant) + inhibitor<br /> | **[[6cj5]], [[6cje]], [[6cjh]], [[6cjw]], [[6cjy]], [[6ck3]], [[6ck6]], [[6cki]] – hChk 2 catalytic domain (mutant) + inhibitor<br /> | ||
| - | *'''hChk Pak''' or '''Chk N''' or '''PRK1''';Domains - CRIB 74-109; | + | *'''hChk Pak''' or '''Chk N''' or '''PRK1''';Domains - CRIB 74-109; Hr1B 122-199; kinase 605-942 |
**[[1urf]] – hChk Pak-1 Hr1b domain - NMR<br /> | **[[1urf]] – hChk Pak-1 Hr1b domain - NMR<br /> | ||
| Line 470: | Line 470: | ||
**[[1zyd]] – yChk Gcn2 + ATP<br /> | **[[1zyd]] – yChk Gcn2 + ATP<br /> | ||
**[[4otn]] – mChk Gcn2 C terminal domain <br /> | **[[4otn]] – mChk Gcn2 C terminal domain <br /> | ||
| - | |||
| - | *'''PRK1''' | ||
| - | |||
| - | **[[4otd]] – hPRK1 catalytic domain <br /> | ||
| - | **[[1urf]] – hPRK1 Hrb1 domain - NMR<br /> | ||
| - | **[[4otg]], [[4oth]], [[4oti]] – hPRK1 catalytic domain + clinical inhibitor<br /> | ||
| - | **[[4nkg]] – hPRK1 Hrb1 domain + SSPH1 LRR domain<br /> | ||
| - | **[[2rmk]] – hPRK1 Hrb1 domain + Rac1 - NMR<br /> | ||
| - | **[[1cxz]] – hPRK1 effector domain + RhoA<br /> | ||
*Pim-2 | *Pim-2 | ||
| Line 490: | Line 481: | ||
**[[1wak]] – hChk Sprk1 <br /> | **[[1wak]] – hChk Sprk1 <br /> | ||
**[[3dak]] – hChk Osr1 kinase domain <br /> | **[[3dak]] – hChk Osr1 kinase domain <br /> | ||
| - | **[[3fpq]], [[4q2a]], [[4pwn]] - hChk Wnk1 kinase domain (mutant)<br /> | ||
**[[4aw2]] – hChk Mrckα kinase domain<br /> | **[[4aw2]] – hChk Mrckα kinase domain<br /> | ||
**[[4pxw]] – hChk Vprbp WD repeat domain (mutant)<br /> | **[[4pxw]] – hChk Vprbp WD repeat domain (mutant)<br /> | ||
| + | **[[1q8z]], [[1zyc]] – yChk <br /> | ||
**[[1how]], [[1zxe]], [[1zy4]] – yChk (mutant)<br /> | **[[1how]], [[1zxe]], [[1zy4]] – yChk (mutant)<br /> | ||
| - | **[[1q8z]], [[1zyc]] – yChk <br /> | ||
**[[1ow5]], [[1x9x]] – yChk Ste11 SAM domain – NMR<br /> | **[[1ow5]], [[1x9x]] – yChk Ste11 SAM domain – NMR<br /> | ||
**[[2kio]], [[2kit]] – yChk Tor1 FATC domain – NMR<br /> | **[[2kio]], [[2kit]] – yChk Tor1 FATC domain – NMR<br /> | ||
| Line 525: | Line 515: | ||
**[[5jzn]] – hChk Dclk1 kinase domain + inhibitor <br /> | **[[5jzn]] – hChk Dclk1 kinase domain + inhibitor <br /> | ||
**[[4crs]] – hChk N2 kinase domain + ATPγS<br /> | **[[4crs]] – hChk N2 kinase domain + ATPγS<br /> | ||
| - | **[[3tku]], [[4ual]] – hChk Mrckβ + inhibitor<br /> | + | **[[3tku]], [[4ual]], [[3qfv]], [[5ote]], [[5otf]] – hChk Mrckβ + inhibitor<br /> |
**[[4uak]] – hChk Mrckβ + ADP<br /> | **[[4uak]] – hChk Mrckβ + ADP<br /> | ||
| - | **[[5aja]] – hChk Vprbp WD repeat domain + VPX + SAMHD1<br /> | + | **[[5aja]], [[4z8l]], [[4cc9]] – hChk Vprbp WD repeat domain + VPX + SAMHD1<br /> |
| + | **[[5jk7]] – hChk Vprbp WD repeat domain + VPX + DDB1 + UDG<br /> | ||
| + | **[[3wa0]], [[4p7i]] – hChk Vprbp residues 1417-1506 + merlin<br /> | ||
**[[4wzx]] – hChk Ulk3 MIT 2 domain + inhibitor<br /> | **[[4wzx]] – hChk Ulk3 MIT 2 domain + inhibitor<br /> | ||
**[[5ci7]] – hChk Ulk1 (mutant) + inhibitor<br /> | **[[5ci7]] – hChk Ulk1 (mutant) + inhibitor<br /> | ||
Revision as of 19:54, 18 September 2018
| |||||||||||
3D structures of serine/threonine protein kinase
Updated on 18-September-2018
References
- ↑ Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003 May;3(5):421-9. PMID:12781359
- ↑ Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004 Nov 15;301(1):60-7. PMID:15501446 doi:http://dx.doi.org/10.1016/j.yexcr.2004.08.016
- ↑ Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005 Jan 10;24(2):287-91. PMID:15640844 doi:http://dx.doi.org/10.1038/sj.onc.1208272
- ↑ Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63. doi: 10.1007/s10555-008-9168-1. PMID:19165420 doi:http://dx.doi.org/10.1007/s10555-008-9168-1
- ↑ Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007 Aug;64(15):1930-44. PMID:17530463 doi:http://dx.doi.org/10.1007/s00018-007-7045-7
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
- ↑ Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017. PMID:22500797 doi:http://dx.doi.org/10.1016/j.cell.2012.03.017
- ↑ Ravindran R, Loebbermann J, Nakaya HI, Khan N, Ma H, Gama L, Machiah DK, Lawson B, Hakimpour P, Wang YC, Li S, Sharma P, Kaufman RJ, Martinez J, Pulendran B. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature. 2016 Mar 24;531(7595):523-7. doi: 10.1038/nature17186. Epub 2016 Mar 16. PMID:26982722 doi:http://dx.doi.org/10.1038/nature17186
- ↑ Atilla-Gokcumen GE, Di Costanzo L, Meggers E. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta. J Biol Inorg Chem. 2010 Sep 7. PMID:20821241 doi:10.1007/s00775-010-0699-x

